Germany Respiratory Devices Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Germany represents one of the most mature respiratory device markets in Europe, anchored by a statutory health insurance system that covers a broad range of respiratory therapies and homecare equipment. The market is valued at roughly USD 1.53 billion in 2025 and is forecast to grow at approximately 5.8% annually, reflecting steady rather than explosive expansion. Within the broader German medical device sector, which exceeds USD 40 billion in annual value, respiratory care forms a well-defined and clinically essential subsegment.

• •2025 market size of approximately USD 1.53 billion, with a CAGR of around 5.8% through 2030.
• •Covers therapeutic devices (ventilators, CPAP/BiPAP, nebulizers, oxygen therapy) and inhaler-based drug delivery systems.
• •Demand is supported by Germany's universal health coverage and strong hospital and homecare infrastructure.

Demographic ageing is the single most influential demand driver, as COPD, obstructive sleep apnea, and chronic respiratory failure all increase sharply in prevalence after age 60. Rising rates of asthma and allergy-related airway disease, alongside residual long-COVID respiratory complications, continue to expand the patient pool requiring ongoing device-based therapy. Germany's favourable reimbursement environment, including statutory insurance coverage of home ventilators and sleep therapy devices, also accelerates adoption and equipment replacement cycles.

• •Ageing population driving higher incidence of COPD, sleep apnea, and chronic respiratory insufficiency.
• •Post-pandemic awareness has increased acceptance of home ventilation, oxygen therapy, and telehealth-enabled monitoring.
• •Reimbursement through Germany's statutory health insurance funds supports widespread prescription of home respiratory equipment.

By product type, the market is typically segmented into therapeutic devices (ventilators, CPAP/BiPAP, nebulizers, oxygen concentrators, humidifiers) and monitoring/diagnostic devices, with inhalers and drug-delivery devices forming a parallel subsegment. Within Germany, demand is concentrated in urban states with large hospital networks such as North Rhine-Westphalia, Bavaria, and Baden-Württemberg, while home-based therapy penetration is comparatively higher in rural regions where patients rely on distributed care models. The inhaler sub-segment alone is projected to reach nearly USD 2 billion by 2035, reflecting its scale relative to other device categories.

• •Therapeutic devices (ventilators, CPAP/BiPAP, nebulizers, oxygen therapy) account for the largest share of revenue.
• •Inhalers represent a substantial parallel sub-segment, projected at roughly USD 1.95 billion by 2035.
• •Highest demand concentrations are in populous states including North Rhine-Westphalia, Bavaria, and Baden-Württemberg.

What are the recent trends and outlook?

The market outlook through 2030 is characterised by gradual but steady expansion rather than high-growth disruption, with continued migration of care from hospitals into home and ambulatory settings. Connected and cloud-enabled respiratory devices are gaining traction, allowing clinicians to remotely monitor therapy adherence and device performance in CPAP and home-ventilation patients. Sustainability, energy efficiency, and quieter device operation are emerging as differentiators, while regulatory tightening under the EU Medical Device Regulation (MDR) is raising compliance costs but reinforcing barriers to entry for lower-quality suppliers.

• •Shift toward home-based respiratory care is accelerating, supported by telehealth and remote monitoring integration.
• •EU MDR compliance is reshaping product portfolios and favouring established manufacturers with strong regulatory infrastructure.
• •Long-term growth is expected to remain in the 5-6% annual range, reaching an estimated USD 2.0-2.1 billion by 2030.